JTT-861 by Japan Tobacco for Systolic Heart Failure: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JTT-861 overview

JTT-861 is under development for the treatment of heart failure with reduced ejection fraction (HFrEF). It is administered through oral route. The drug candidate acts by targeting pyruvate dehydrogenase kinase.

Japan Tobacco overview

Japan Tobacco (JT Group) is a manufacturer of cigarettes. The company also manufactures, markets, and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread, and frozen bread, packaged cooked rice, bakery goods, yeast extracts and seasoning, prescription drugs, and generic drugs. JT Group distributes its products through supermarkets, street and train station kiosks, convenience stores, small independent retailers, and vending machines. It caters to retail, industrial and commercial customers in Europe, Africa, the Middle East, Asia-Pacific, and the Americas, and other regions. JT Group is headquartered in Minato-Ku, Tokyo, Japan.

For a complete picture of JTT-861’s drug-specific PTSR and LoA scores, buy the report here.